Skip to Content
Contact DCTD
Show menu
Search this site
Last Updated: 03/30/2023

2023 American Association for Cancer Research Annual Meeting

Schedule of DCTD Presentations

DCTD-supported research will be presented at the AACR Annual Meeting External Link  from April 14-19, 2023.

The following tables include presentations containing DCTD staff speakers and co-authors.

Oral Presentations

Date/Time Title/DCTD Speaker ID
April 16
5:00-5:15
S1512: High response rate with single agent anti-PD-1 in patients with metastatic desmoplastic melanoma External Link CT009
April 18
12:30-1:30
Helping Extramural Innovators Reach the Clinic: NCI Developmental Therapeutics Program External Link
Rosemarie Aurigemma, PhD, Sundar Venkatachalam, PhD, Sharad K. Verma, PhD, Marc S. Ernstoff, MD
NIH09
April 18
2:30-4:30
Molecular Targets Session External Link
Chairperson: Naoko Takebe, MD, PhD
MS.ET06.01
April 18
3:22-3:37
An integrated immune signature predictive of adjuvant immunotherapeutic benefits for high-risk melanoma External Link 5704
April 18
3:22-3:37
Combination therapies in matched 3D in vitro and in vivo preclinical models of rare and recalcitrant cancers from the National Cancer Institute's Patient-Derived Models Repository External Link 5720
April 18
3:22-3:37
Advancing a screening platform with panels of patient-derived organoid models for drug discovery and development External Link 5776

Poster Presentations

Date/Time Title/DCTD Presenter (If Applicable) ID
April 16
1:30 PM - 5:00 PM
Comparing twenty-two matched patient-derived cell lines developed from either patient, PDX, or organoid tumor cell material External Link 36/4
NCI patient derived models repository: PDX, organoid and cell lines from the same patient - bridging the translational pipeline External Link 40/8
Establishment and characterization of a novel clear cell sarcoma organoid model derived from a human biopsy External Link 154/6
Determinants of birinapant efficacy in triple negative breast cancer External Link 393/19
April 17
9:00 AM - 12:30 PM
NCI’s clinical proteomic tumor analysis consortium analysis tools and resources External Link 2019/3
Molecular subclassification of NCI PDMR breast cancer models using PAM50 gene expression signature External Link 2050/19
Proteomic-based stemness score measure oncogenic dedifferentiation and enable the identification of druggable targets External Link LB061/4
April 17
1:30 PM - 5:00 PM
Biochemical inhibition profiles of 370 wild type human kinases provide a basis for selecting alternative combinations of EGFR and VEGFR inhibitors External Link 2665/1
Pharmacokinetics, bioavailability, and pharmacodynamics of oral triapine External Link 2800/23
Combination of talimogene laherparepvec (T-VEC) with pembrolizumab (pembro) in advanced melanoma patients following progression on a prior PD-1 inhibitor: SWOG S1607 External Link 3275/16
Olaparib +/- atezolizumab in patients with BRCA-mutated (BRCAmt) locally advanced unresectable or metastatic (advanced) breast cancer: an open-label, multicenter, randomized phase II trial External Link CT145/7
A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the non-epithelial ovarian tumor cohort External Link CT161/23
A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the small cell carcinoma of the ovary, hypercalcemic type cohort External Link CT163/25
Recurrence score for recurrence over survival outcome in the landmark TAILORx trial External Link LB119/2
April 18
9:00 AM - 12:30 PM
CT194 / 7 - ETCTN 10388: a first in human phase I trial of triapine and lutetium Lu 177 DOTATATE in well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) External Link CT194/7
April 18
1:30 PM - 5:00 PM
Aryl-hydrocarbon receptor inhibitors in combination with anticancer agents, especially proteasome pathway inhibitors, in a complex spheroid screen using patient-derived cell lines can result in greater-than additive cytotoxicity External Link
Beverly Teicher, PhD
4555/6
Targeted investigational oncology agents (IOA) in the NCI60: a phenotypic systems-based resource External Link
Joel Morris, PhD
4884/27
A pan-cancer PDX histology image repository with genomic and pathological annotations for deep learning analysis External Link 5407/23
April 19
9:00 AM - 12:30 PM
Antibody validation for clinical pharmacodynamic assay reveals cross-reactivity of commercial DNMT3B clones External Link 6008/11
Chromosomal aneuploidy, whole-genome doubling and mutational signatures in NCI PDMR models External Link 6072/12
Novel multiplexed assays of ferroptosis, pyroptosis and necroptosis biomarkers for translational studies External Link 6143/5

Meet-the-Expert Presentations

Date/Time Topic Presenter
April 17
11:30 AM
Funding Opportunities for the Development of Tumor Site-Activated Small Molecules Sharad Verma, PhD
Developmental Therapeutics Program
April 17
2:00 PM
Program Project (P01) Grant Development Guidance Aniruddha Ganguly, PhD
Cancer Diagnosis Program
April 17
3:00 PM
3D Cell Culture Screening at NCI Using Patient-Derived Models Beverly Teicher, PhD
Developmental Therapeutics Program
April 18
11:30 AM
Biospecimen Resources for the Research Community: Cooperative Human Tissue Network, NCI National Clinical Trials Network and Specimen Resource Locator Irina Lubensky, MD
Cancer Diagnosis Program
Aniruddha Ganguly, PhD
Cancer Diagnosis Program
April 18
3:00 PM
NCI Experimental Therapeutics (NExT) Program: A Government, Academic, Industry Partnership for Cancer Drug Discovery and Development John Giraldes, MS
NCI Experimental Therapeutics Program

Staff Kiosk Schedule – Exhibit Booth #809

Date Time Presenter
April 16 1:00 – 3:00 pm Aniruddha Ganguly, PhD
Cancer Diagnosis Program
Marco Cardone, PhD
Developmental Therapeutics Program
3:00 – 5:00 pm Joseph Agyin, PhD, MBA
Developmental Therapeutics Program
Sumana Dey, PhD
Cancer Diagnosis Program
April 17 9:00 – 11: 00 am Joanne Demchok, MS, BS
Cancer Diagnosis Program
Morgan O’Hayre, PhD
Developmental Therapeutics Program
11:00 – 1:00 pm Beverly Teicher, PhD
Developmental Therapeutics Program
1:00 – 3:00 pm Christophe Marchand, PhD
Developmental Therapeutics Program
3:00 – 5:00 pm Sundar Venkatachalam, PhD
Developmental Therapeutics Program
April 18 9:00 -11:00 am Naveena Janakiram, PhD
Translational Research Program
Weiwei Chen, PhD
Developmental Therapeutics Program
11:00 – 1:00 pm Sharad Verma, PhD
Developmental Therapeutics Program
Aniruddha Ganguly, PhD
Cancer Diagnosis Program
1:00 – 3:00 pm Leah Hubbard, PhD
Translational Research Program
3:00 – 5:00 pm Marc S. Ernstoff, MD
Developmental Therapeutics Program
April 19 9:00 – 12:00 pm Aniruddha Ganguly, PhD
Cancer Diagnosis Program